---
run_id: halo-evidence-vs-diagnosis-validation-v10-generic-advice-prompted-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: generic_advice_prompted
run_number: 1
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 105
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `generic_advice_prompted`, run 1 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 105, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (expansion bookings, renewals) look strong, but your leading indicators (adjuster abandonment, "unexplainable" actions in health-liability, and managers using the tool for auditing rather than production) suggest that DraftPath is providing **perceived value to buyers** but not **realized value for users**.

The "Commercial Cleanroom" is too risky; it tests whether you can sell the product, but you already know you *can* sell it—the problem is whether the product actually works. The "Usage Quality Sprint" is a vanity metric trap; tracking return rates tells you *that* users are leaving, but not *why*.

The **Claim File Review** is the only option that addresses the "black box" problem. In B2B workflow software, especially in regulated insurance, the gap between a "proposed action" and an "executed action" is where churn lives. By auditing the files, you will discover if adjusters are overriding DraftPath because it is wrong, or because they lack the "explainability" required for compliance. This tells you if DraftPath is a product problem (bad logic) or an enablement problem (bad UI/documentation).

### Tradeoffs and Sacrifices
By choosing the Claim File Review, you are explicitly sacrificing **commercial certainty** and **speed of scale**.
*   **Giving up the Cleanroom:** You will not know for certain if the recent revenue spike was purely a result of the bundle pricing and roadmap hype. You are betting that product-market fit is more important than price-point validation right now.
*   **Giving up the Quality Sprint:** You will lack a real-time dashboard of usage. You are trading "big data" (how many people clicked) for "thick data" (why the adjuster ignored this specific suggestion).

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. While you are spending weeks reviewing files, your competitors may be scaling faster, and your sales team may lose momentum because they aren't getting new "roadmap" promises to dangle in front of buyers. If the problem is actually a pricing/packaging issue rather than a utility issue, this review will be a distraction that fails to fix the revenue engine.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "unexplainable" actions in health-liability are actually a legal requirement that cannot be solved by software (i.e., the adjuster *must* write the note manually for compliance). If the product is fundamentally blocked by regulation regardless of how "correct" the AI is, then DraftPath is a niche feature, not a core product. In that case, the only remaining question is how to price it for the non-regulated segments, making the Cleanroom the priority.
